Healthy Clinical Trial
— CBD-FocusOfficial title:
Cannabidiol and Focus Study (CBD-Focus)
Verified date | September 2023 |
Source | University of Northern Colorado |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Cannabidiol (CBD), a non-psychoactive hemp derivative, is an attractive therapeutic target, and is most supported by the scientific community as an antiepileptic, anxiolytic, and antipsychotic. Additionally, CBD may cause alterations in aspects of health and fitness, fatigue, stress, calmness, quality of life, cognitive function, ability to maintain focus, sleep quantity, and sleep quality. Cannabidiol may be associated with alterations in inflammatory response in the human body, which has implications in both healthy and diseased populations. Natural killers cells (NKC) play a vital role in maintain your body's defenses and are an essential component of your immune system. In humans, NKC contain the highest concentrations of receptors associated with the endocannabinoid system and CBD. Human models have demonstrated that CBD use increases the percentage of NKC in peripheral blood. However, similar models found that CBD administration inhibits markers of NKC cytotoxic function, a beneficial cellular mechanism used to prevent malignant cell transformation and viral infection. The overarching goal of this investigation is to determine the effects of an 8-week CBD intervention on measures of fatigue, stress, calmness, quality of life, cognitive function, focus, health and fitness, and sleep quantity, and sleep quality. In addition, this study will explore a potential CBD mechanism of action with a focus on biomarkers of neural health, inflammation, liver health, kidney health, as well as NKC number and function.
Status | Completed |
Enrollment | 100 |
Est. completion date | December 31, 2022 |
Est. primary completion date | December 31, 2022 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 50 Years |
Eligibility | Inclusion Criteria: - Currently completing at least 150 minutes of moderate to vigorous physical activity per week - Have a body mass index under 29.9 - No significant physical or mental health (without the presence of chronic depression or anxiety) conditions - No presence or past diagnosis of eating disorders Exclusion Criteria: - Subjects may not have an allergy to soy. - All study subjects must also be free of cannabis product use or regular high doses of antioxidants for the previous 8 weeks. Participants receive a $200 Visa Gift Card after the last study visit is completed. |
Country | Name | City | State |
---|---|---|---|
United States | University Of Northern Colorado | Greeley | Colorado |
Lead Sponsor | Collaborator |
---|---|
University of Northern Colorado |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in Quality of Life Questionnaire Score | Ferrans and Powers Quality of Life Index Questionnaire. A higher scores suggests higher quality of life. | Just before the 8 Week Intervention and Immediately Following the 8 Week Intervention | |
Primary | Change in Fatigue Score | Piper Fatigue Questionnaire. A higher score suggests higher levels of fatigue. | Just before the 8 Week Intervention and Immediately Following the 8 Week Intervention | |
Primary | Change in Sleep Assessment | Sleep Assessment (7 day). We will use Fitbits to track sleep. | Just before the 8 Week Intervention and in the 7th Week of the 8 Week Intervention | |
Primary | Change in Sleep Questionnaire Score | Leeds Sleep Questionnaire. Lower scores generally suggest better sleep. | Just before the 8 Week Intervention and Immediately Following the 8 Week Intervention | |
Primary | Change in Physical Activity (steps per day) | Physical Activity Assessment (7 day). We will use Fitbits to track physical activity. | Just before the 8 Week Intervention and in the 7th Week of the 8 Week Intervention | |
Primary | Change in Perceived Stress Scale Score | Perceived Stress Questionnaire. A higher score suggests higher perceived stress. | Just before the 8 Week Intervention and Immediately Following the 8 Week Intervention | |
Primary | Change in General Anxiety Disorder Questionnaire Score | General Anxiety Disorder Questionnaire 7. A higher score suggests higher levels of anxiety. | Just before the 8 Week Intervention and Immediately Following the 8 Week Intervention | |
Primary | Change in Psychological Wellbeing Scale Score | Psychological Wellbeing Questionnaire. A higher score suggests better wellbeing. | Just before the 8 Week Intervention and Immediately Following the 8 Week Intervention | |
Primary | Change in Cognitive Function and Abilities Score | Patient-Reported Outcomes Measurement Information System (PROMIS) Cognitive Function Abilities - Short Form 8a. A higher score suggests higher cognitive ability. | Just before the 8 Week Intervention and Immediately Following the 8 Week Intervention | |
Primary | Change In Cognitive Function Score | PROMIS Cognitive Function - Short Form 8a. A higher score suggests higher cognitive ability. | Just before the 8 Week Intervention and Immediately Following the 8 Week Intervention | |
Primary | Change in Athlete Sickness and Illness Assessment Score | The Wisconsin Upper Respiratory Symptom Survey. A higher scores suggests more respiratory symptoms. | Just before the 8 Week Intervention and Immediately Following the 8 Week Intervention | |
Primary | Change in Sustained Attention to Response Task (SART) Activity | Sustained Attention to Response Task (SART) Activity | Just before the 8 Week Intervention and Immediately Following the 8 Week Intervention | |
Primary | Change in Maximal Anaerobic Power | Wingate Power Test | Just before the 8 Week Intervention and Immediately Following the 8 Week Intervention | |
Primary | Change in Natural Killer (NK) Cell Number | NK Cell Counts obtained on a flow cytometer. | Just before the 8 Week Intervention and Immediately Following the 8 Week Intervention | |
Primary | Change in Natural Killer (NK) Cell Function | NK Cell Cellular Function Assay using Flow Cytometry | Just before the 8 Week Intervention and Immediately Following the 8 Week Intervention | |
Primary | Change in a Biomarker of Inflammation | Serum C-Reactive Protein | Just before the 8 Week Intervention and Immediately Following the 8 Week Intervention | |
Primary | Change in a Biomarker of Neural Health | Circulating Brain Derived Neurotropic Factor | Just before the 8 Week Intervention and Immediately Following the 8 Week Intervention | |
Primary | Change in a Stress Biomarker | Serum Cortisol | Just before the 8 Week Intervention and Immediately Following the 8 Week Intervention | |
Primary | Change in Liver Health Biomarker I | Serum Aspartate aminotransferase (AST) | Just before the 8 Week Intervention and Immediately Following the 8 Week Intervention | |
Primary | Change in Liver Health Biomarker II | Serum Alanine aminotransferase (ALT) | Just before the 8 Week Intervention and Immediately Following the 8 Week Intervention | |
Primary | Change in Kidney Health Biomarker | Serum creatinine | Just before the 8 Week Intervention and Immediately Following the 8 Week Intervention |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06052553 -
A Study of TopSpin360 Training Device
|
N/A | |
Completed |
NCT05511077 -
Biomarkers of Oat Product Intake: The BiOAT Marker Study
|
N/A | |
Recruiting |
NCT04632485 -
Early Detection of Vascular Dysfunction Using Biomarkers From Lagrangian Carotid Strain Imaging
|
||
Completed |
NCT05931237 -
Cranberry Flavan-3-ols Consumption and Gut Microbiota in Healthy Adults
|
N/A | |
Completed |
NCT04527718 -
Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers
|
Phase 1 | |
Terminated |
NCT04556032 -
Effects of Ergothioneine on Cognition, Mood, and Sleep in Healthy Adult Men and Women
|
N/A | |
Completed |
NCT04065295 -
A Study to Test How Well Healthy Men Tolerate Different Doses of BI 1356225
|
Phase 1 | |
Completed |
NCT04998695 -
Health Effects of Consuming Olive Pomace Oil
|
N/A | |
Completed |
NCT04107441 -
AX-8 Drug Safety, Tolerability and Plasma Levels in Healthy Subjects
|
Phase 1 | |
Completed |
NCT01442831 -
Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects
|
Phase 1 | |
Terminated |
NCT05934942 -
A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood
|
Phase 1 | |
Recruiting |
NCT05525845 -
Studying the Hedonic and Homeostatic Regulation of Food Intake Using Functional MRI
|
N/A | |
Completed |
NCT05515328 -
A Study in Healthy Men to Test How BI 685509 is Processed in the Body
|
Phase 1 | |
Completed |
NCT04967157 -
Cognitive Effects of Citicoline on Attention in Healthy Men and Women
|
N/A | |
Completed |
NCT05030857 -
Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy Subjects
|
Phase 1 | |
Recruiting |
NCT04494269 -
A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls
|
Phase 1 | |
Recruiting |
NCT04714294 -
Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT04539756 -
Writing Activities and Emotions
|
N/A | |
Recruiting |
NCT04098510 -
Concentration of MitoQ in Human Skeletal Muscle
|
N/A | |
Completed |
NCT03308110 -
Bioavailability and Food Effect Study of Two Formulations of PF-06650833
|
Phase 1 |